The double-blind, randomized, placebo-controlled study is designed to evaluate the safety and effectiveness of treating stroke patients with MultiStem, an off-the-shelf stem cell treatment derived from the bone marrow of adults or other non-embryonic sources.
- The trial is scheduled to start enrollment this month, with 10/13 estimated as the time frame for final data collection and is expected to be completed by 11/14.
The Bottom Line: ATHX believes MultiStem could represent a significant advancement in treating ischemic stroke patients. The technology has shown promise in reducing inflammation, protecting damaged tissue and forming new blood vessels. Ischemic stroke is caused by a blood clot in the brain and accounts for 87% of all stroke cases.
Stroke is the most promising application of MultiStem which is also being investigated for the treatment of heart attack, inflammatory bowel disease, orthopedics and blood diseases.